Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-Effectiveness of Opportunistic Osteoporosis Screening Using Chest Radiographs With Deep Learning in the United States.

Journal of the American College of Radiology : JACR·2025
Same author

Cost-effectiveness of radiofrequency echographic multi-spectrometry for the diagnosis of osteoporosis in the United States.

JBMR plus·2024
Same author

Clinical and demographic factors determining patient fracture risk decision point (FRDP): The improving risk communication in osteoporosis (RICO) project.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2024
Same author

Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2024
Same author

Race-specific FRAX models are evidence-based and support equitable care: a response to the ASBMR Task Force report on Clinical Algorithms for Fracture Risk.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2024
Same author

Comparison of the cost-effectiveness of sequential treatment with abaloparatide in US men and women at very high risk of fractures.

Aging clinical and experimental research·2024
Same journal

Beyond Fracture Probability: Communicating the Full Consequences of Fracture and Contextualization.

Current osteoporosis reports·2026
Same journal

Time-Lapse HR-pQCT: an in Vivo Imaging-Based Assessment of Bone Remodeling Dynamics.

Current osteoporosis reports·2026
Same journal

Cone Beam Computed Tomography of Bonejaws in Patients With Primary Osteoporosis: A Systematic Review.

Current osteoporosis reports·2026
Same journal

Testosterone and Bone Health in Men.

Current osteoporosis reports·2026
Same journal

Stimulant Medications and Bone Health.

Current osteoporosis reports·2026
Same journal

The Innate and Adaptive Immune Functions of Osteoblast-Lineage Cells.

Current osteoporosis reports·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

New selective estrogen receptor modulators (SERMs) in development.

Stuart L Silverman1

  • 1Cedars-Sinai/UCLA, 8641 Wilshire Boulevard, Suite 301, Beverly Hills, CA 90211, USA. stuarts@omcresearch.org

Current Osteoporosis Reports
|July 7, 2010
PubMed
Summary
This summary is machine-generated.

Selective estrogen receptor modulators (SERMs) offer dual benefits for osteoporosis and breast cancer risk reduction. Newer SERMs like arzoxifene, bazedoxifene, and lasofoxifene show promise with improved safety profiles compared to older agents.

More Related Videos

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Related Experiment Videos

Last Updated: Jun 11, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Area of Science:

  • Endocrinology and Pharmacology
  • Bone and Breast Health

Background:

  • Selective estrogen receptor modulators (SERMs) are estrogen agonists/antagonists with potential benefits for osteoporosis and breast cancer.
  • SERMs are classified by core structure, with triphenylethylenes (e.g., tamoxifen) limited by endometrial stimulation.
  • Benzothiophenes (e.g., raloxifene) and indole-based SERMs (e.g., bazedoxifene) offer skeletal benefits with minimal uterine effects.

Purpose of the Study:

  • To review raloxifene and three newer SERMs: arzoxifene, bazedoxifene, and lasofoxifene.
  • To discuss the effects of these SERMs on bone, breast, and cardiovascular systems.
  • To evaluate the safety profiles of these emerging SERMs.

Main Methods:

  • Review of scientific literature on SERMs.
  • Analysis of clinical studies focusing on efficacy and safety.
  • Comparison of different SERM classes and their therapeutic applications.

Main Results:

  • Benzothiophene and indole-based SERMs demonstrate skeletal benefits with reduced uterine stimulation.
  • Emerging SERMs (arzoxifene, bazedoxifene, lasofoxifene) are under investigation for their therapeutic potential.
  • Comprehensive evaluation of effects on bone, breast, cardiovascular health, and overall safety is ongoing.

Conclusions:

  • Newer SERMs, including arzoxifene, bazedoxifene, and lasofoxifene, represent advancements in osteoporosis and breast cancer prevention.
  • These agents offer a potentially improved therapeutic profile compared to earlier SERMs.
  • Further research is crucial to fully elucidate their long-term benefits and safety.